江一平教授治疗乙型肝炎肝硬化代偿期用药规律研究*

邱宽, 徐如龙, 张智, 江一平

中西医结合肝病杂志 ›› 2024, Vol. 34 ›› Issue (7) : 613-618.

PDF(5133 KB)
PDF(5133 KB)
中西医结合肝病杂志 ›› 2024, Vol. 34 ›› Issue (7) : 613-618. DOI: 10.3969/j.issn.1005-0264.2024.007.008
循证医学

江一平教授治疗乙型肝炎肝硬化代偿期用药规律研究*

  • 邱宽1, 徐如龙2△, 张智2, 江一平3
作者信息 +

Study on the medication rule of professor Jiang Yiping in treating hepatitis B cirrhosis based on data mining

  • QIU Kuan1, XU Ru-long2△, HANG Zhi2, et al
Author information +
文章历史 +

摘要

目的: 探讨江一平教授治疗乙型肝炎肝硬化代偿期的处方用药规律。方法: 收集整理江一平教授治疗乙型肝炎肝硬化代偿期患者的病案,运用IBM SPSS Modeler 18及IBM SPSS Statistics 26.0的关联分析和聚类分析等方法,对用用药及方剂规则进行归纳。结果: 中药频次分析的前10位中药为鳖甲、丹参、柴胡、甘草、川芎、当归、三棱、莪术、陈皮、生地。气滞血瘀痰凝型的核心药对为莪术、三棱,莪术、鳖甲;肝郁脾虚型的核心药对为柴胡、甘草,柴胡、党参;肝郁气滞型的核心药对为柴胡、香附,香附、陈皮;湿热中阻型的核心药对为茵陈、大黄,金钱草、大黄;气虚血亏型的核心药对为黄芪、当归,谷芽、麦芽。气滞血瘀痰凝型代表性处方为血府逐瘀汤类方;肝郁脾虚型代表性处方为柴芍六君汤类方和保和丸类方;肝郁气滞型代表性处方为柴胡疏肝散类方;湿热中阻型代表性处方为茵陈蒿汤类方;气虚血亏型代表性处方为当归补血汤类方、归脾汤类方和四君子汤类方。结论: 江一平教授重视化瘀软坚散结、健脾养肝、清利湿热、扶正祛邪的治法治则,善用活血化瘀类、软坚散结类、清热类、补虚类、疏肝类药物治疗乙型肝炎肝硬化代偿期。

Abstract

Objective: To explore the prescription rule of Professor Jiang Yiping in the compensatory treatment of hepatitis B cirrhosis. Methods: Collect and sorted out the medical records of Professor Jiang Yiping in the treatment of patients with compensated hepatitis B cirrhosis, and summarized the association analysis and cluster analysis by the methods of IBM SPSS Modeler 18 and IBM SPSS Statistics 26.0. Results: The top ten Chinese medicines in the frequency analysis of Chinese medicine were: turtle jia, Salvia miltiorrhiza, Bupleurum, licorice, Chuanxiong, Angelica, SanLeng, zedoary, tangerine peel and raw ground. Qi stagnation blood stasis sputum coagulation type of core drugs for zedoary, three edges, zedoary, turtle armour. The core medicine for liver depression and spleen deficiency type is bupleurum, licorice, bupleurum, and Dangshen. The core drugs of liver stagnation type are bupleurum, incense, incense, and tangerine peel. The core medicine of resistance type in damp and heat has wormwood, rhubarb, money grass, and rhubarb. Gas deficiency of blood deficiency type of the core drugs for astragalus, angelica, grain bud, and malt. The representative prescription of qi stagnation, blood stasis, and phlegm coagulation is blood mansion. The representative prescription for liver depression and spleen deficiency is Chai Shao Liujun soup prescription and Baohe pill prescription. The representative prescription of liver stagnation and qi stagnation is buhu liver dispersing formula. The representative prescription of liver stagnation and qi stagnation is buhu liver dispersing formula. The representative prescription of resistance in damp and heat is Yin Chen artemisia soup. The representative prescription of resistance in damp and heat is wormwood soup. The representative prescriptions of qi deficiency and blood deficiency are angelica blood tonic soup, spleen soup, and four gentleman soup. Conclusion: Professor Jiang Yiping attaches great importance to the treatment of removing blood stasis, soft and dispersing, invigorating spleen and liver, clearing dampness and heat, and making good use of blood circulation and removing blood stasis drugs, soft and dispersing drugs, heat clearing drugs, deficiency drugs, and liver thinning drugs to treat the compensation period of hepatitis B cirrhosis.

关键词

乙型肝炎 / 肝硬化代偿期 / 数据挖掘

Key words

hepatitis B / compensatory stage of cirrhosis / data mining

引用本文

导出引用
邱宽, 徐如龙, 张智, 江一平. 江一平教授治疗乙型肝炎肝硬化代偿期用药规律研究*[J]. 中西医结合肝病杂志, 2024, 34(7): 613-618 https://doi.org/10.3969/j.issn.1005-0264.2024.007.008
QIU Kuan, XU Ru-long, HANG Zhi, et al. Study on the medication rule of professor Jiang Yiping in treating hepatitis B cirrhosis based on data mining[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2024, 34(7): 613-618 https://doi.org/10.3969/j.issn.1005-0264.2024.007.008
中图分类号: R575.1   

参考文献

[1] Yue MW, Li YH, Wu HM, et al. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis[J]. Clin Exp Med,2017,17(2): 233-241.
[2] Ghany MG. Current treatment guidelines of chronic hepatitis B: the role ofnucleos(t)ide analogues and peginterferon[J]. Best Pract Res Clin Gastroenterol,2017,31(3):299-309.
[3] 中华医学会感染病学分会,中华医学会肝病分会.慢性乙型肝炎防治指南(2019年版)[J].中国病毒病杂志,2020,10(1):1-25.
[4] 中国中西医结合学会消化系统疾病专业委员会.肝硬化中西医结合诊疗共识[J].中国中西医结合消化杂志,2011,19(4):277-279.
[5] 中华中医药学会肝胆病专业委员会.慢性乙型肝炎中医诊疗指南(2018年版)[J].中西医结合肝病杂志,2019,29(1):97-102.
[6] 高建蓉,朱有法,张赤志,等.鳖甲水煎液对两种肝纤维化大鼠模型的实验研究[J].中华中医药学刊,2009,27(8):1727-1733.
[7] 吴航.丹参酚酸B通过Sirt-1对大鼠肝纤维化模型的影响[J].华北理工大学学报(医学版),2016,18(5):349-352.
[8] Wang K, Wang J, Song M, et al. Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathw-ay[J]. Int J Biol Macromol, 2020,162(162):273-283.
[9] 王海兰,何娟,曹文富,等.川芎含药血清对肝星状细胞Toll样受体4及下游信号因子MyD88表达的影响[J].中国中药杂志,2015,40(11):2191-2194.
[10] 郑洋,卢能源,黄永贤,等.基于TGF-β1/Smad信号通路探讨莪术醇对肝纤维化小鼠作用的实验研究[J]. 中华中医药学刊,2021,39(11):149-152.
[11] 董毅玲,覃志成.三棱内酯B的药理作用研究进展[J].现代药物与临床,2022,37(10):2402-2407.
[12] 任建琳,王健,胡晔,等.柴胡皂苷d对免疫性肝纤维化大鼠TGF-β1、HYP、SOD、MDA的影响[J].现代预防医学,2012,39(12):3044-3047.
[13] 张炜,毕小利,马文欢.生地干预特发性肺间质纤维化转化生长因子β受体表达的实验研究[J].中国中西医结合杂志,2003(s1):79-82.
[14] 曾兵,廖柏鸿,周东耀,等.陈皮酵素可体内抑制小鼠的肝纤维化[J].南方医科大学学报,2021,41(4): 588-592.
[15] 赵金英.甘草黄酮抗硫代乙酰胺诱导大鼠肝纤维化的作用以及机制研究[D].宁夏医科大学,2012.
[16] 栾希英,李珂珂,韩兆东,等.三棱、莪术对肝纤维化大鼠IL-1、IL-6、TNF-α的影响[J].中国免疫学杂志,2004,20(12):834-837.
[17] 熊莎.鳖甲抗肝纤维化活性肽的分离鉴定及其作用机制研究[D].湖北中医药大学,2018.
[18] 赵敏崎,韩德五,马学惠,等.甘草甜素、甘草次酸与柴胡皂甙对防治大白鼠实验性肝硬化的作用[J].药学学报,1983(5):325-331.
[19] Liu C, Chen J, Li E, et al. The comparison of antioxidative and hepatoprotective activities of Codonopsis pilosula polysaccharide (CP) and sulfated CP[J]. Int Immunopharmacol, 2015,24(2):299-305.
[20] 尚双艳,高翔.香附多糖对牛血清白蛋白诱导的肝纤维化大鼠血清MMP-2、TIMP-2和TGF-β1水平的影响[J].实用肝脏病杂志,2018,21(1):42-45.
[21] 刘玉萍,邱小玉,刘烨,等.茵陈的药理作用研究进展[J].中草药,2019,50(9):2235-2241.
[22] 展玉涛,刘宾,李定国,等.大黄素抗肝纤维化的作用机制[J].中华肝脏病杂志,2004,11(4):58-59.
[23] 李军,蔡泓,王君明,等.金钱草化学成分、药理作用及临床应用[J].中国老年学杂志,2017,37(24):6262-6264.
[24] 孙墨晗,赵哲,靳玉秋,等.黄芪当归配伍对抗肝纤维化的作用研究[J].医学信息,2022,35(8):17-20.
[25] 刘翔.江一平治疗慢性肝炎肝纤维化经验[J].江西中医药,2007,55(4):8-9.
[26] 徐如龙,熊雯雯,江一平.江一平辨治肝病传脾经验介绍[J].新中医,2019,51(11):336-337.

基金

江西省中医药中青年骨干人才(第三批)培养计划项目[赣中医药科教字(2021)4号],江一平全国名老中医药专家传承工作室建设项目〔国中医药人教函[2022]75号〕
PDF(5133 KB)

598

Accesses

0

Citation

Detail

段落导航
相关文章

/